期刊文献+

血管性痴呆和血管性认知障碍的临床研究进展 被引量:9

Diagnosis and Management of Vascular Cognitive Impairment and Dementia
下载PDF
导出
摘要 血管性认知障碍和痴呆是认知障碍和痴呆领域以及脑血管病领域研究方面的交叉点。本文综述了血管性痴呆和认知障碍的定义、诊断标准和药物治疗进展。在诊断方面重点介绍了血管性痴呆各个亚型的临床特点。在治疗方面重点介绍了血管性痴呆和认知障碍的胆碱能递质代谢障碍以及胆碱酯酶抑制剂治疗的进展。 Vascular dementias(VaDs)are the second most common cause of dementia.Vascular cognitive impairment(VCI)and dementias extend beyond the traditional multi-infarct dementia.Variation in defining the cognitive syndrome,in vascular etiologies,and allowable brain changes in current criteria have resulted in variable estimates of prevalence,of groups of subjects,and of the types and distribution of putative causal brain lesions.Ideally in constructing new criteria the diagnostic elements should be tested with prospective studies with clinical-pathological correlation.Meanwhile focus on more homogenous subtypes of VaD,and on imaging criteria could be a solution.Subcortical ischemic vascular dementia(SIVD)incorporates small vessel disease as the chief vascular etiology,lacunar infarct and ischaemic white matter lesions as primary type of brain lesions.In addition to simple co-existence,VaD and AD have closer interaction.Vascular cognitive impairment(VCI)is a spectrum that includes subtle cognitive deficits of vascular origin,post-stroke dementia,and the complex group of the vascular dementias.Recently symptomatic cholinergic treatment has shown promise in AD with VaD,as well as probable VaD.Future focus should be directed to the distinct etiological and pathological factors.
作者 冯涛
出处 《中国卒中杂志》 2006年第10期736-740,共5页 Chinese Journal of Stroke
关键词 痴呆 血管性 认知障碍 Dementia,Vascular Cognitive impairment
  • 相关文献

参考文献21

  • 1[1]Erkinjuntti T.Cerebrovascular dementia:pathophysiology,diagnosis and treatment[J].CNS Drugs,1999,12:35-48.
  • 2[2]Roman GC,Erkinjuntti T,Wallin A,et al.Subcortical ischaemic vascular dementia[J].Lancet Neurol,2002,1:426-436.
  • 3[3]Gold G,Bouras C,Canuto A,et al.Clinicopathological validation dtudy of gour dets of clinical criteria for vascular dementia[J].Am J Psychiatry,2002,159:82-87.
  • 4[4]O' Brien JT,Erkinjuntti T,Reisberg B,et al.Vascular cognitive impairment[J].Lancet Neurol,2003,2:89-98.
  • 5[5]Sawada T,Whitehouse PJ.Regulatory guidelines for antidementia drugs.In:Erkinjuntti T,Gauthier S,eds.Vascular Cognitive Impairment.London:UK:Martin Duniz Ltd,2002:619-627.
  • 6[6]Ferris S,Gauthier S.Cognitive outcome measures in vascular dementia.In:Erkinjuntii T,Gauthier S,eds.Vascular Cognitive Impairment.London:UK:Martin Duniz Ltd,2002:395-400.
  • 7[7]Quinn J,Moore M,Benson DF,et al.A videotaped CIBIC for dementia patients:validity and reliability in a simulated clinical trial[J].Neurology,2002,58:433-437.
  • 8[8]Orgogozo JM,Rigaud AS,Stoffier A,et al.Efficacy and safety of memantine in patients with mild to moderate vascular dementia:a randomized,placebo-controlled trial (MMM 300)[J].Stroke,2002,33:1834-1839.
  • 9[9]Mielke R,Moller HJ,Erkinjuntti T,et al.Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia:overview of phase Ⅰ and phase Ⅱ clinical trials[J].Alzheimer Dis Assoc Disord,1998,12:29-35.
  • 10[10]Antoni L,Bianchi C,Beneke M,et al.The scandinavian multiinfarct dementia trial:a double-blind,placebo-controlled trial on nimodipine in multi-infarct dementia[J].J Neurol SCI,2000,175:116-123.

同被引文献107

引证文献9

二级引证文献162

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部